Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 12, December, p. 1667–1673

doi: 10.17219/acem/110316

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Acute coronary syndrome in patients undergoing anticancer therapies: A single-center, controlled case study

Izabela Nabiałek-Trojanowska1,2,B,C,D, Alicja Dąbrowska-Kugacka2,E, Zuzanna Lewicka-Potocka1,2,C,D,E, Yasmina Abdulaziz2,B,C,D, Anna Szerszyńska2,B,C,D, Grzegorz Raczak2,E, Ewa Lewicka2,A,E,F

1 First Department of Cardiology, Medical University of Gdańsk, Poland

2 Department of Cardiology and Electrotherapy, Medical University of Gdańsk, Poland

Abstract

Background. Anticancer therapies can be accompanied by cardiovascular complications, including acute coronary syndrome (ACS). In turn, the presence of cancer can influence therapeutic decisions if ACS occurs.
Objectives. The aim of the study was to analyze ACS treatment in patients with cancer.
Material and Methods. The study consisted of a retrospective analysis based on the medical records of patients who were admitted due to ACS, with cancer diagnoses. Patients currently undergoing cancer treatment or having treatment which ended up to 6 months before the ACS were included. They were compared to a control group consisting of consecutive patients admitted for ACS during the same period, but who did not have a diagnosis of cancer; they were matched with the experimental group in terms of age, gender and clinical type of ACS.
Results. Thirty-two consecutive cancer patients (70 ±9 years; 53% men) met the inclusion criteria. In 22 of them (69%), ACS occurred during their cancer treatment, and in 10 (31%), it presented within 6 months of completing cancer treatment. Upon hospital admission, 19 (59%) cancer patients complained of dyspnea and 7 of typical angina, while in the control group 28, (87%) and 4 (13%) reported such symptoms, respectively.The clinical manifestation of ACS was NSTEMI in 16 patients (50%), UA in 10 (31%) and STEMI in 5 (15.6%). Coronary angiography was done in 25 (78%) of the cancer patients and in all members of the control group. Percutaneous coronary angioplasty (PCA) was performed in 17 (53%) and 23 (72%) of the patients from the respective groups. The median time to percutaneous coronary intervention (PCI) was 10 h (30 min–10 days) among the cancer patients and 7.5 h among the control group (30 min–6 days). There were no PCI-related complications or severe bleeding in both groups. In-hospital mortality was 6.25% in the cancer group and there were no reported hospital deaths in the control group.
Conclusion. Dyspnea is the most common symptom of ACS in cancer patients who are treated invasively too rarely: the presence of cancer and active anticancer treatment should not limit the management of ACS in accordance with current guidelines.

Key words

acute coronary syndrome, anticancer therapy, STEMI, NSTEMI, cancer disease

References (27)

  1. Landes U, Kornowski R, Bental T, et al. Long-term outcomes after percutaneous coronary interventions in cancer survivors. Coron Artery Dis. 2017;28(1):5–10.
  2. Goldberg R, Chen H-Y, Saczynski J, et al. The impact of cardiac and noncardiac comorbidities on the short-term outcomes of patients hospitalized with acute myocardial infarction: A population-based perspective. Clin Epidemiol. 2013;5:439–448.
  3. Hess CN, Roe MT. Treatment of coronary artery disease in cancer survivors. Coron Artery Dis. 2017;28(1):1–2.
  4. Mozzini C, Garbin U, Fratta Pasini AM, Cominacini L. An exploratory look at NETosis in atherosclerosis. Intern Emerg Med. 2017;12(1):13–22.
  5. Hasin T, Iakobishvili Z, Weisz G. Associated risk of malignancy in patients with cardiovascular disease: Evidence and possible mechanism. Am J Med. 2017;130(7):780–785.
  6. Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70(8):926–938.
  7. Yeh ETH, Chang H-M. Cancer and clot: Between a rock and a hard place. J Am Coll Cardiol. 2017;70(8):939–941.
  8. Caine GJ, Stonelake PS, Lip GYH, Kehoe ST. The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia. 2002;4(6):465–473.
  9. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768–2801.
  10. Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with cancer and cancer survivors. J Am Coll Cardiol. 2015;65(25):2739–2746.
  11. Herrmann J, Yang EH, Iliescu CA, et al. Vascular toxicities of cancer therapies: The old and the new. An evolving avenue. Circulation. 2016;133(13):1272–1289.
  12. Wrona A, Dziadziuszko R, Jassem J, et al. Radioterapia a ryzyko powikłań ze strony układu sercowo-naczyniowego. In: Szymański F, Filipiak K, eds. Nieklasyczne Czynniki Ryzyka Chorób Układu Sercowo-Naczyniowego w Gabinecie Lekarza Praktyka. Warsaw: ITEM Publishing; 2017:137–158.
  13. Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(8):721–740.
  14. Munoz E, Iliescu G, Vejpongsa P, et al. Takotsubo stress cardiomyopathy: Good news in cancer patients? J Am Coll Cardiol. 2016;68(10):1143–1144.
  15. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315.
  16. Yusuf SW, Daraban N, Abbasi N, et al. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443–450.
  17. Banasiak W, Zymliński R, Undas A. Optimal management of cancer patients with acute coronary syndrome. Polish Arch Intern Med. 2018;128(4):244–253.
  18. Iliescu C, Tsitlakidou D, Giza DE, Marmagkiolis K. Primary percutaneous coronary interventions in cancer patients. Cancer Res Front. 2017;3(1):64–71.
  19. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol. 2016;142(2):471–479.
  20. Velders MA, Boden H, Hofma SH, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol. 2013;112(12):1867–1872.
  21. Gale CP, Allan V, Cattle BA, et al. Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003–2010: A multilevel and relative survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR). Heart. 2014;100(7):582–589.
  22. Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308(10):998–1006.
  23. Wojtkowska I, Stępińska J, Stępień-Wojno M, et al. Current patterns of antithrombotic and revascularisation therapy in patients hospitalised for acute coronary syndromes. Data from the Polish subset of the EPICOR study. Kardiol Pol. 2017;75(5):445–452.
  24. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: National cohort study. BMJ. 2009;338(19):b1807–b1807.
  25. Sciahbasi A, Fischetti D, Picciolo A, et al. Transradial access compared with femoral puncture closure devices in percutaneous coronary procedures. Int J Cardiol. 2009;137(3):199–205.
  26. Iliescu CA, Grines CL, Herrmann J, et al. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Intervencion. Catheter Cardiovasc Interv. 2016;87(5):E202–223.
  27. Sarkiss MG, Yusuf SW, Warneke CL, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109(3):621–627.
© Wroclaw Medical University